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Tumor  necrosis  factor (TNF)  was identified by Carswell  et al.  (1)  during a 
study  of  the  antitumor  activity  of  serum  from  mice  infected  with  bacillus 
Calmette-Guerin and subsequently injected with endotoxin. In a  recent report 
(2), it was observed that human B cell lines produce a factor that is cytotoxic for 
mouse  L  cells sensitive to  mouse TNF  but  not for  L  cells  resistant  to  mouse 
TNF.  The cytotoxic factor from one B  cell  line (LuKII) was partially purified 
and found to cause hemorrhagic necrosis of the Meth A  mouse sarcoma in the 
standard in vivo mouse TNF assay (2).  Based on these observations and other 
biological  similarities  to  mouse  TNF,  this  factor has  been  designated  human 
TNF(LuKII). 
TNF(LuKII) has now been purified to a specific activity of 1.5 ×  10 7 U/mg of 
protein (3). Examination of this material by sodium dodecyl sulphate-polyacryl- 
amide  gel  electrophoresis  (SDS-PAGE)  demonstrates  the  presence  of  seven 
protein bands with molecular weights ranging from 80,000  to  19,000  (3).  The 
higher molecular weight forms are  not aggregates of lower molecular weight 
components, as they cannot be dissociated by SDS, 2-mercaptoethanol, or urea. 
Peptide  mapping  analysis,  as  well  as  studies  using a  monoclonal  antibody to 
TNF(LuKII), have demonstrated that all of the proteins present in these TNF 
preparations are related (3). 
Many  biologically active  molecules,  including  hormones  and  lymphokines, 
have  been  found to  bind  to specific cell  surface receptors.  In  the  case of the 
interferons, it has been observed that resistance to the biological effects of an 
interferon can  be due  to a  lack of appropriate  cell  surface  receptors  (4).  Cell 
lines  of human  and  mouse  origin  differ in  their  sensitivity to  the  cytotoxic/ 
cytostatic effect of TNF  (1,  5-7) and cells grown in the presence  of TNF can 
become resistant  to the effect of TNF  (2).  In  this study, we demonstrate  the 
existence of cell surface receptors to TNF and show that ceils made resistant to 
TNF do not bind TNF(LuKII). 
Materials and Methods 
TNF Preparations  and Assay.  TNF(LuKII) was purified from culture  fluids of the 
human LuKII lymphoblastoid cell line after induction with 10 ng/mi of mezerein (L. C. 
This work was supported by grants CA-38661 and CA-08748 from the National Cancer Institute. 
J. Exe. MED. © The Rockefeller University Press - 0022-1007/85/09/1099/06  $1.00  1099 
Volume 162  September  1985  1099-1104 1100  RUB1N  ET  AL.  BRIEF  DEFINITIVE  REPORT 
Services,  Woburn, MA) (3). The specific activity of the TNF(LuKII) preparation was 1.5 
X 107 U/mg of protein. Mouse serum TNF was purified by DEAE and G-100 Sephadex 
column chromatography and had a specific activity of 5 x  104 U/mg of protein. A more 
highly purified preparation of mouse TNF (1  X 106 U/mg protein) was a gift of Dr. K. 
Haranaka. 
TNF assays were performed in 96-well microtiter plates.  TNF-sensitive L(M) cells were 
added at a  density of 2  x  104 cells/well  in  100 #1 to fractions of TNF serially  diluted 
twofold. After 2 d at 37°C, the plates were examined microscopically and the percentage 
of the killed  cells was determined. The number of units of sample was calculated as the 
reciprocal of the highest dilution that killed  50% of the cells. All TNF assays were run in 
parallel with a TNF(LuKII) laboratory standard and all titers are expressed in laboratory 
units. 
Radioiodination of TNF(LuKII).  TNF(LuKII) was  labeled  with  lz~I using  1,3,4,6- 
tetrachloro-3a,6a-diphenylglycoluril (Iodo-gen; Pierce  Chemical Co.,  Rockford, IL) in 
the following manner. Polypropylene tubes were coated with 100 #g of Iodo-gen (dissolved 
in chloroform) by evaporation of  the solvent. A sample of TNF(LuKII) containing 160,000 
U/ml (as assayed in duplicate on three occasions)  in  3  ml was incubated for 25 min at 
room temperature  in  an  Iodo-gen-coated tube  containing 6  mCi  of 1~5I. The  labeled 
protein was then separated from the unbound 125I using a P-4 column (Bio-Rad Labora- 
tories, Richmond, CA) equilibrated with phosphate-buffered saline  (PBS) containing 50 
ttg/ml of cytochrome c. The iodinated material eluted in the void volume of the column 
in 8 ml and was divided into aliquots before storing at -80°C. It was assayed for biological 
activity six times on separate occasions and was found to contain 60,000 U/ml and 7.5 × 
109 cpm/mg of TNF(LuKII). Thus, radioiodination of TNF(LuKII) did not result in any 
apparent loss of biological activity. 
Assay  for the Binding of t25I-labeled TNF(LuKII) to Cells.  L(M) cells and TNF-resistant 
subclones of L(M) cells seeded in 25-cm  2 flasks at a density of 2 X 106 cells per flask were 
allowed to adhere to the flasks for 24 h before exposure to ~I-labeled TNF(LuKII); at 
this time, the flasks contained ~3.5  x  106 cells per flask.  HeLa cells seeded in  25-cm  ~ 
flasks at a density of 1.5 X 106 cells per flask were allowed to adhere to the flasks for 48 
h before exposure to ~25I-labeled TNF(LuKII); at this time, the flasks contained ~5 x  106 
cells per flask.  ~25I-labeled TNF(LuKII) was added to the flasks in 1 ml Eagle's minimum 
essential  medium (MEM), containing 10% fetal bovine serum (Gibco Laboratories, Grand 
Island,  NY).  Amounts of TNF and time  intervals are  described in  the figure  legends. 
After the indicated incubation period, the cells were washed three times with cold PBS, 
scraped from the flask in PBS, and centrifuged at  15,000 g for 5 min over a cushion of 
PBS containing 5% sucrose. The sucrose cushion was then removed and the cell pellets 
counted in a gamma radiation counter. Specific binding of the radiolabeled TNF(LuKII) 
was determined by subtracting the number of counts bound to cells in the presence of an 
excess  of nonlabeled TNF(LuKII) from the  number of counts in the presence of tesI- 
labeled TNF(LuKII) alone. The amount of nonlabeled TNF(LuKII) used in each exper- 
iment is stated in the figure legends. Nonspecific binding of ~SI-labeled  TNF(LuKII) was 
not >15 cpm in any experiment. 
Results 
Mouse  L(M) cells and  HeLa cells (a  line derived from human cervical carci- 
noma) are sensitive  to the cytotoxic effect of TNF(LuKII) and mouse TNF.  L 
cells can be rendered resistant  to TNF by repeated passage in TNF-containing 
medium, and two sublines of TNF-resistant L(M) cells have been developed: one 
made resistant to mouse TNF and the other, resistant to TNF(LuKII). Resistance 
to mouse TNF renders the cells resistant to TNF(LuKII), and vice versa. 
As  a  first  step,  we  examined  the  time  course  of  binding  of  ~25I-labeled 
TNF(LuKII) to the  L(M) cells,  L(M) cells resistant  to TNF(LuKII), and  HeLa 
cells. As shown in Fig.  1, the specific binding of ~25I-labeled TNF(LuKII) to the RUBIN  ET  AL.  BRIEF  DEFINITIVE  REPORT  1101 
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FIGURE  1.  Time course of ~51-TNF(LuKII) binding. L(M) (I), L(M) resistant to TNF(LuKI1) 
(A), and HeLa cells (0) were incubated for increasing lengths of time in the presence of either 
75 U/ml of ~251-1abeled TNF(LuKII) or 75 U/ml of L2nI-labeled  TNF(LuKII) plus 1,875  U/ 
ml of nonlabeled TNF(LuKII). After the time intervals indicated, the cells were harvested. 
Curves represent the specific counts bound (see Materials and Methods). Experiments were 
performed at 4°C (A) and at 37°C (B). 
FIGURE 2.  Competitive binding of 1251-TNF(LuKII) by TNF(LuKII) and mouse TNF. L(M) 
(A) and HeLa (B) cells were incubated for 4 h with either 75 U/ml of I~51-TNF(LuKII) alone 
(control)  or  with  75  U/ml  of  J2Sl-TNF(LuKII)  and  increasing amounts  of nonlabeled 
TNF(LuKII) (0) or mouse TNF (O). All values are expressed as a percentage of the  ~bl- 
TNF(LuKII) bound in the absence of nonlabeled TNF. 
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FIGURE 3.  Saturation of 125I-TNF(LuKII)  binding to L(M) and HeLa cells.  L(M) (A) and 
HeLa cells (B) were incubated for 5 h with increasing amounts of 12Sl-TNF(LuKII) or with 
increasing amounts of ]2SI-TNF(LuKII)  and  11,250  U/ml of nonlabeled TNF(LuKII). The 
cells were harvested and the specific cpm bound was determined. Curves represent the specific 
counts bound, determined as described in Material and Methods. 
FIGVRE 4.  Cytotoxic effect of TNF(LuKII) on L(M) and HeLa cells. L(M) cells (A) seeded 
at a density of 2 ×  106 cells per 25-cm * flask and HeLa cells (B) seeded at a density of 0.5 x 
106 cells per 25-cm z flask were allowed to incubate for 24 and 48 h, respectively. The media 
was  then  removed  and  replaced  with  media  containing  increasing  concentrations  of 
TNF(LuKII). The percentage of viable cells was determined 30 h later using trypan blue. 
L(M)  and  HeLa  cell  lines occurred  rapidly at  4°C  and  reached  a  steady state 
within 4  h.  At 37 ° C, the amount  of radiolabeled TNF(LuKII)  bound  to the cells 
continued  to increase even after 8  h  incubation. The  amount  of specific binding 
of  125I-labeled TNF(LuKII)  is  higher  at  37°C  than  at  4°C.  Comparable  tests 
with  L  cells resistant  to  mouse  TNF  or  TNF(LuKII)  showed  no  specific  ]25I- 
labeled TNF(LuKII)  binding even after 8  h  exposure. 
Quantitative  competition  experiments  revealed  that  the  binding  of  125I- 
labeled TNF(LuKII)  to  L(M)  or  HeLa  cells is equally  inhibited  by nonlabeled 
TNF(LuKII)  and mouse TNF  (Fig. 2). 
To  determine  whether  binding of TNF(LuKII)  to the cells was occurring  via 
a  saturable receptor, we incubated  L(M) and HeLa  cells with increasing concen- 
trations of ]25I-labeled TNF(LuKII)  for  5  h  at  4°C  and  measured  the  uptake. 
Sites  for  TNF(LuKII)  on  L(M)  and  HeLa  cell  lines  are  half  saturable  at  a 
TNF(LuKII)  concentration  of-  100  U/ml,  demonstrating  the presence of high 
affinity  binding  sites  (Fig.  3).  Three  additional  experiments  were  performed 1102  RUBIN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 5.  Scatchard analysis of the binding data depicted in Fig. 3.  Specific binding was 
converted into Scatchard plots for the L(M) (A) and HeLa (B) cell lines. 
(data not shown) and similar saturation cuFves were observed.  Examination of 
the cytotoxic effect of TNF(LuKII) on  L(M) and HeLa cells (Fig. 4) revealed 
that the receptor saturation curves and the dose response curves are  roughly 
similar in their concentration dependence. Scatchard plots of the data in Fig. 3 
are shown in Fig.  5.  Based on TNF(LuKII) having a  molecular weight, under 
nondenaturing conditions, of 70,000  (2,  3) and a specific activity of 1.5  ×  10 7 
U/mg of protein, we calculate the number of TNF receptors to be approximately 
200  and  300  for the  L(M) and  HeLa cell  lines, respectively, and the binding 
constant to be ~1  x  10  -1° M for both L(M) and HeLa cells. 
Discussion 
Purified ~25I-labeled TNF(LuKII) bound specifically to saturable high affinity 
receptors present on cell lines sensitive to the cytotoxic effect of TNF(LuKII) or 
mouse  TNF.  Cell  lines  rendered  resistant  to  TNF  appeared  to  lack  specific 
receptors for TNF(LuKII). At 4°C, the binding of radiolabeled TNF(LuKII) to 
sensitive cells reached equilibrium after 4  h  of exposure,  while, at  37°C,  the 
amount of TNF(LuKII) bound to the cells continued to increase over 8 h. These 
results suggest possible uptake or metabolism of the radiolabeled TNF(LuKII) 
at 37°C. 
Mouse serum TNF competes with TNF(LuKII) for receptor binding on both 
mouse and human cell  lines. Since the mouse TNF preparation used in these 
studies was not pure, the competition observed may be due to the contaminants. 
However, the observation that equal numbers of units of TNF(LuKII) and mouse 
TNF result in a  similar degree of competition and that preparations of mouse 
TNF with different specific activities compete to an equivalent extent (data not 
shown) suggest that mouse TNF molecules are competing with TNF(LuKII) for 
receptor binding. It will be important to carry out a similar receptor studies with 
recombinant human TNF (8-10) and nonrecombinant and recombinant human 
lymphotoxin (11,  12) to determine whether a common receptor exists for these 
various cytotoxic factors. 
Under denaturing conditions, TNF(LuKII) is observed to exist in molecular 
weight  forms ranging from  80,000  to  19,000  (3)  and,  under  nondenaturing 
conditions, as  a  70,000  tool  wt  molecule.  We  have  used  this  latter  value  to 
calculate the  number  of receptors  per  cell  and  the  binding  constant  of the 
receptor. The number of receptors would be higher if we calculated on the basis 
of the lower molecular weight forms of TNF(LuKII). RUBIN  ET  AL.  BRIEF  DEFINITIVE REPORT  1103 
Williamson et al. (2) have defined the TNF(LuKII) sensitivity of a  large panel 
of human  cell lines,  and  studies are currently  underway to determine whether 
TNF response correlates with the presence and number of TNF receptors. If so, 
tests for TNF  receptors on tumor biopsies may be of predictive value in deter- 
mining the TNF  sensitivity of individual tumors. 
Summary 
125I-labeled TNF(LuKII)  (tumor necrosis  factor) binds  specifically to  human 
and  mouse cell  lines  sensitive to  the  cytotoxic effect of TNF,  but  not  to  cells 
made  resistant  to  TNF.  TNF-sensitive  cells  have  cell  surface  receptors  with  a 
high  affinity  for  TNF(LuKII).  Mouse  TNF  competes  with  TNF(LuKII)  for 
receptor binding.  Scatchard analysis of the binding data yielded linear plots and 
suggests that TNF(LuKII) binds to homogeneous receptor sites. The number of 
TNF(LuKII) receptors on  two TNF-sensitive cell  lines is 200-300  per cell and 
the affinity constant of the receptor for TNF(LuKII) is ~1  x  10  -l° M. 
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Note added  in proof." Recombinant  human TNF provided  by Dr. Michael Pallidino, Genentech, 
Inc., competes with TNF(LuKII) for TNF receptor binding. 
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